Updates on Chimeric Antigen Receptor T-Cells in Large B-Cell Lymphoma

CD19-targeting chimeric antigen receptor (CAR) T-cells have changed the treatment paradigm of patients with large B-cell lymphoma (LBCL). Three CAR T-cells were approved by the Food and Drug Administration (FDA) for patients with relapsed and/or refractory (R/R) LBCL in the third-line setting: tisag...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Khalil Saleh, Nadine Khalife, Ahmadreza Arbab, Rita Khoury, Claude Chahine, Rebecca Ibrahim, Zamzam Tikriti, Nohad Masri, Mohamad Hachem, Axel Le Cesne
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	MDPI AG 2024-12-01
Цуврал:	Biomedicines
Нөхцлүүд:	CD19-targeting CAR T-cells lisocabtagene maraleucel axicabtagene ciloleucel tisagenlecleucel large B-cell lymphoma
Онлайн хандалт:	https://www.mdpi.com/2227-9059/12/12/2810
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!